Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation antiepileptic drugs (AEDs) currently available, and they must make adjustments throughout a patient’s disease course to achieve optimal seizure control. Understanding the evolving patient journey in epilepsy provides important context about the complex, saturated, and heavily generic drug market that developers of new AED brands will enter. Based on national patient-level claims data, this report explores the use of key therapies in both newly diagnosed and recently treated patients, examines line of therapy progression, and assesses persistence and compliance by brand.
Markets covered: United States
Key companies: UCB, Eisai, SK Biopharmaceuticals, Azurity Pharmaceuticals, Jazz Pharmaceuticals, Neurelis
Key drugs: First-generation AEDs, second-generation AEDs; including Trokendi XR, Oxtellar XR, Eprontia; third-generation AEDs, including Briviact, Fycompa, Aptiom, Epidiolex, Diacomit, Xcopri, Fintepla; and outpatient rescue therapies, including Nayzilam and Valto
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.